Terfenadine Articles
Enrollment "well on track" for Ph III TLT trial
28 January 2008
Argentina bans terfenadine and astemizole
8 September 2003
GW, S-P push steroids for allergic rhinitis
7 July 1999
Fexofenadine linked to arrhythmia case
29 March 1999
Sepracor tops analysts' biotech stocks
20 January 1999
Lilly Licenses Prozac Successor
8 December 1998
US FDA Proposed Rule On Banned Drugs
13 October 1998
Hoechst Sales Down 18% But HMR Pipeline Strong
19 August 1998
Warnings To Be Added To US Propulsid Labeling
1 July 1998
Hoechst Confirms Life Science Focus
5 May 1998
Bad Times Soon Over, Says Hoechst Marion Roussel
12 March 1998
EMEA CPMP Plenary Meeting In February
10 March 1998
Expanded Warnings For J&J's Hismanal
11 February 1998
HMR Pulls Seldane
2 January 1998
Hoechst Nine-Month Profits Plunge 49%
25 November 1997
UK Gives Terfenadine Prescription-Only Status
4 September 1997
Hoechst Realignment Reflected In Interim Result
13 August 1997
Hoechst Warns Of A Tough Year Of Changes
12 May 1997
CSM Curbs Terfenadine Use In UK
5 May 1997
No Flotation For Hoechst's HMR, At Least Not Now
17 March 1997
Positive Verdict On Roche's Posicor From FDA Panel
10 March 1997
HMR Launches Telfast 120 In The UK
3 March 1997
France Withdraws HMR's Teldane Approval
24 February 1997
S-P Rapped Over Claritin Ads
17 February 1997
HMR Pushes Allegra As It Faces Possible Seldane Ban
20 January 1997
USA Approves Sporanox Pulse Dosing
23 December 1996
WFPMM Hears Self-Medication Warning
18 November 1996
Synthelabo Pipeline Supports "Seven Key Product" Strategy
21 October 1996
Accolate Cleared In USA For Asthma; 1st In Class
7 October 1996
Fexofenadine Launched In Its First Market
2 September 1996
Hoechst Gain US Allergy Drug Approval
5 August 1996
US FDA Seeks Comments On Consumer Ad Labeling
27 May 1996
Sustained-Release Fexofenadine
29 April 1996
Hiccup For Zeneca With FDA Panel Accolate Verdict
8 April 1996
Correction: Terfenadine Patent Dispute
26 February 1996
New US Boycott Of HMR Over RU 486
26 February 1996
HMR Terfenadine Verdict
19 February 1996
First Generic Terfenadine?
12 February 1996
R-PR's Antihistamine Roll-Out Gathers Speed
30 October 1995
Guide To Investing In Biotechnology Companies
29 May 1995
Are OTC Makers Targeting The Right markets?
8 May 1995
....And Marion Merrell Dow Updates On R&D Efforts
10 April 1995
Triludan Adverse Reactions
20 March 1995
Sepracor Moving Ahead In Its Chirality Field
13 March 1995
Hoechst Offers $7 Billion For Marion Merrell Dow
6 March 1995
Reimbursement Prices Higher In Japan Than Overseas
16 January 1995
Sepracor Shares Up On US Patent News
16 January 1995
B-MS' Nefazodone: Launch Soon In USA
9 January 1995
Solvay Gains Luvox Approval From FDA
19 December 1994
S-P's Claritin-D Approved In USA
21 November 1994
Lower Earnings For Some US Drugmakers In 3rd Qtr
7 November 1994
Global Respiratory Market 1993-2000
31 October 1994
Generics To Lead US Managed Care "Soon"
17 October 1994
DOW CHEM MAY SELL ITS MMD STAKE
27 June 1994
MMD FILES LAWSUIT OVER SELDANE PATENT
27 June 1994
GENERIC THREAT TO AUGMENTIN IN UK
6 June 1994
US CHEMICAL/DRUG COs SHOW 1st QTR GROWTH
9 May 1994
MMD INCREASES HOLDING IN KODAMA
11 April 1994
DELISTING "PRODUCES ARTIFICIAL GROWTH"
28 March 1994
MMD TO FILE SUIT OVER SELDANE FORM
14 March 1994
MYLAN ACQUIRES GENERIC SELDANE-D RIGHTS
7 March 1994
MYLAN PRODUCT ACQUISITION
14 February 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
MARKET WARMS TO COUGH & COLD SEASON IN USA
1 November 1993
US 3rd QTR RESULTS MIXED AS DRUG IND CUTS BACK
25 October 1993
CHANGES TO UK DRUG STATUS
16 August 1993
DELISTING AND OTC SALES IN DENMARK
26 July 1993
PENDING APPLICATIONS IN US CONTINUE TO DWINDLE
19 July 1993
SMITHKLINE BEECHAM CORPORATE OTC STRATEGY
5 July 1993
UK WANTS TERFENADINE WARNINGS ADVERTISED
7 June 1993
EARNINGS GROWTH EXPANSION SEEN FOR UCB
31 May 1993
SEMPREX-D BACKED FOR HAYFEVER
17 May 1993
CLARITIN LAUNCH IN USA
26 April 1993
OTC TAVIST SHOWS RAPID GROWTH
12 April 1993
BROAD SPECTRUM WAY FORWARD IN ANTIFUNGALS
12 April 1993
TERFENEDINE AND KETOCONAZOLE STUDY
22 March 1993
WORLD RESPIRATORY PRODUCTS MARKET
1 March 1993
RECORD RESULTS FROM US PHARMA MAJORS
1 February 1993
ACICLOVIR SHOULD GO OTC, SAYS UK MCA
1 February 1993
SCHERING-PLOUGH'S CLARITYN GOES OTC
1 February 1993
US OTC ANALGESICS - A 1992 RETROSPECTIVE
4 January 1993
SWITCHING POM TO OTC IN THE UK
14 December 1992
MARRION MERREL DOW APPOINTMENTS
7 December 1992
US CHEMICAL/PHARMA COS' POOR PERFORMANCE
9 November 1992
RX-TO-OTC SWITCHING FOR SUCCESS
2 November 1992
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs
3 August 1992
CANADA TOUGHENS ANTIHISTAMINES STANCE
3 August 1992
GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR
27 April 1992
1991 A "SUPERB" YEAR FOR MARION MERRELL DOW
13 April 1992
NORTH AMERICA'S OTC COUGH COLD MARKET
9 March 1992
US GENERIC DRUG MARKET TO 1995
17 February 1992
RECORD 4TH QTR FROM US DRUG COMPANIES
10 February 1992
TOUGH TIMES AHEAD FOR MARION MERRELL DOW?
27 January 1992
Showing 1-100 of 100 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
